Member Info for EmeraldCarrots

Below the offer price of 15p, just (ask 14.5p).

Co is on the books. When that lands what's the betting the sp will go North of the 15p placing and open offer price? Dead cert I'd say.

All IMHO.

Have now placed orders with Angle. These are for Angle to use their patented Parsortix machine to catch circulating tumour cells from the blood stream of people who have cancer. Then for Angle to analyse them in ways that simply cannot be done using Ctdna analysis of the blood. Only the original tumour (before being cut out) and the circulating tumour cells have this information. Simple as that. Companies like Illumina and Thermo Fisher simply must know that analysing the circulating tumour cells can give very valuable information. Information that simply cannot be obtained by analysing blood CtDna (fragments of DNA in the blood) because it does not exist in these DNA fragments!

The big Pharma Co’s know this, and it is concerning more of the massive Pharma Co’s have not, as yet, placed orders with Angle Plc. Hopefully now Astrazeneca have placed a couple of orders things will really start to move.

All IMHO.

Conclusion. Angle shares are on the verge of going 50p plus. Apart from anything else (and there is a lot of other things they are involved with), just their services arm are likely within 12 months to be generating millions of pounds. Likely to snowball from there to tens of millions of pounds. The Parsortix machine enables the capture (from a standard blood sample) of circulating tumour cells (cancerous cells in the blood stream that have come from the original tumour). With their Parsortix system 99% of the cells are alive, perfect for analysing not only the DNA. Also, the proteins and RNA too, which CANNOT BE DONE USING CtDna analysis of the blood. Therefore, Circulating Tumour Analysis offers information that simply is not available from CtDna, because that information is not there, as in missing from the DNA fragments.

The Services side has the following contracts to date.

1. Eisai Inc. "ANGLE's Portrait HER2 assay provides a way to evaluate HER2 status in patients where a tissue biopsy at the metastatic site either fails or is not feasible.". Note there are loads of cancer drug trials where they need to know the HER2 status of a patient throughout the treatment as it can change.

2. Astrazeneca. “ANGLE will develop a novel methodology for CTC micronuclei detection based on its existing pKAP1 CTC-based DDR assay, which measures expression of a key protein in the DNA damage response.

3. Astrazeneca. “agreement to develop a Parsortix-based Androgen Receptor1 (AR) detection assay for use in prostate cancer studies.”.

IMHO this list will expand to 5, 8, 12, 18, 26, 35 etc…….

Waiting for the RNS’s………………..

All IMHO...

Look closely.

https://www.youtube.com/watch?v=5Bdw7iZr3ac

Conclusion. Angle shares are on the verge of going 50p plus. Apart from anything else (and there is a lot of other things they are involved with), just their services arm are likely within 12 months to be generating millions of pounds. Likely to snowball from there to tens of millions of pounds. The Parsortix machine enables the capture (from a standard blood sample) of circulating tumour cells (cancerous cells in the blood stream that have come from the original tumour). With their Parsortix system 99% of the cells are alive, perfect for analysing not only the DNA. Also, the proteins and RNA too, which CANNOT BE DONE USING CtDna analysis of the blood. Therefore, Circulating Tumour Analysis offers information that simply is not available from CtDna, because that information is not there, as in missing from the DNA fragments.

The Services side has the following contracts to date.

1. Eisai Inc. "ANGLE's Portrait HER2 assay provides a way to evaluate HER2 status in patients where a tissue biopsy at the metastatic site either fails or is not feasible.". Note there are loads of cancer drug trials where they need to know the HER2 status of a patient throughout the treatment as it can change.

2. Astrazeneca. “ANGLE will develop a novel methodology for CTC micronuclei detection based on its existing pKAP1 CTC-based DDR assay, which measures expression of a key protein in the DNA damage response.

3. Astrazeneca. “agreement to develop a Parsortix-based Androgen Receptor1 (AR) detection assay for use in prostate cancer studies.”.

IMHO this list will expand to 5, 8, 12, 18, 26, 35 etc…….

Waiting for the RNS’s………………..

All IMHO.

You don't. Looking forward to the next Pharma Co. to place an order following the ones from Astrazeneca and Eisai. Obviously will happen.

The big Pharma Co's with the big budgets should employ Companies like Angle who are at the cutting edge of liquid biopsy advances. The truth is it is early days as far as what can be gained by analysing circulating tumour cells. As they are the very cells that can spread a cancer it's obvious, they must contain valuable information to do with the cancer. Only by analysing the cancer cells before, during and after a cancer treatment will we find out what a drug has done (if anything) to slow or hopefully eliminate the cancer. The amazing thing to me is some cancer treatments sometimes work very well and sometimes they don't. As I understand it, they don't fully understand why. The contracts so far with Eisai and Astrazeneca will throw more light on what analysing the circulating tumour cells can tell us. Personally, I think it is a disgrace that more of the huge Pharma Co's have not yet employed Angle's expertise to find out what information the circulating tumour cells can give us during the trials. I suspect it is cost, and this is why in my opinion it is a disgrace. How on earth can these massive Pharma Co’s justify doing a cancer drug trial WITHOUT analysing the circulating tumour cells? Apart from anything else there is quite obviously a very good chance of the data being extremely useful. I mean, these are cancerous cells from the original tumour. If they have not got important information what on Earth does? The following RNS’s about the “CTC & ctDNA dual analysis” show one of the ways Angle can help.

https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html

https://www.lse.co.uk/rns/AGL/parsortix-and-assays-being-showcased-at-eacr-2024-xhvpvzmogvybaro.html

All IMHO.

Should give the airline shares a boost. Also fuel costs a lot lower.

TOTALLY under rated by the market in my opinion. I mean, the ability to more accurately monitor the effect of any cancer drug during a drug trial! What Pharma Co. planning a cancer drug trial is going to NOT want it? They would be failing in their duty would they not? What are they going to say? We considered collecting blood samples before, during and after the trial for Angle Plc. This was to analyse and report on changes to the CtDna in the blood and the DNA changes to the Circulating tumour cells which we know happen and might give us valuable information. However, we thought we would risk not bothering with this information to save some money and keep our fingers crossed the information would not prove to be important now or in the future. LOL!

https://www.lse.co.uk/rns/AGL/parsortix-and-assays-being-showcased-at-eacr-2024-xhvpvzmogvybaro.html

All IMHO.

"1. Targeted sequencing of circulating tumour cells captured by the Parsortix system enables low frequency variant analysis with pan-cancer Next Generation Sequencing (NGS) panel. The dual analysis of CTCs and circulating tumour DNA (ctDNA) is emerging as a workflow to provide a more comprehensive analysis of a patient's cancer.".

This is for use during cancer drug trials. The aim of any drug trial is obviously to collect, assess, and record for future reference any and all changes caused by the drug being tested. From now on any Companies doing cancer drug trials need to decide if they want this additional data about the effect of their new drug. If they choose not to, they risk potentially important information being missed and not recorded for future reference. This is why I believe this will be a massive money spinner for angle. It seems to me potentially one of more of the massive Pharma Co’s like Astrazeneca could want this information for all of their cancer drug trials going forward.

https://www.lse.co.uk/rns/AGL/parsortix-and-assays-being-showcased-at-eacr-2024-xhvpvzmogvybaro.html

All IMHO.

Seems to have caused you to blow a fuse. I wonder why? Have you somehow shorted Angle Plc? I remember last Nov when the sp was sub 10p you posted the sp should be more like 4p. Got that one a tad wrong by the looks. I bet you can't wait for confirmation of the next contract from Astrazeneca, Eisai or the like?

All IMHO.

Following last week’s placing and open offer @ 15p a share.

Often a good time to buy just after a placing to raise cash.

Personally, I think it is obvious that Angle will secure additional contracts from Astrazeneca, Eisai and the like going forward.

From the RNS: " Completion of the fundraising alongside delivery of market expectations is anticipated by the Company to secure cashflow breakeven on a monthly basis by the end of 2025".

All IMHO.

TwoGood2Die.

Even for you your rants since the placing tell me either you have a short that is so far under it's down a mine shaft or you need help due to a mental issue. Can't you see why. Look at your posts!

Something that TwoGood2Die failed to mention of course.

I had already pointed this out in an earlier reply but I assume 2Good did not like it, reported it and it was removed.

The moderator on this site sometimes does not seem to read the posts that are complained about, just delete them.

TwoGood2Die knows this and I believe has perfectly good posts removed on a regular basis.

Https://www.youtube.com/watch?v=5YMak8EP1NE

Eisai Inc. are proof that, finally, Angle are starting to deliver the goods. It is there in black and white! Angle only need a few more additional "household name" multi Billion pound market cap Companies to start using them on a reasonably regular basis and they will be not only breaking even but making a profit. Chill.

Director buys expected any day.

All IMHO.

And I will be taking up as many as I can in the open offer @ 15p each. No one knows for sure what the future will bring of course. With me, the bottom line is Angle are finally landing contracts with some of the Largest multi Billion market cap Companies in the World. Indeed they now have the 2 with Astrazeneca, the 7th largest pharma Co. IN THE ENTIRE WORLD. This is massively important. Companies like Eisai Inc. of Japan (top 100 Japanese Plc) and Astrazeneca don't place orders with small Companies like Angle unless they really need what Angle can offer. They would have looked at who in the market place could give them what they want and they have chosen Angle Plc.

All IMHO.

Correction.

Any one of the 2 Astrazeneca and one Eisai contracts to date could make millions of pounds.

It's totally ludicrous! I'm loaded up with these BIGTIME............ Over £20k...........

All IMHO.

Takeover bid?

If you believe Angle will be able to secure more contracts from the 50 or so Pharma Co's in the Wolrd with market caps over $15 BILLION then it might be a good idea to buy Angle shares. Especially as they have now got contrcts with Astrazeneca (7th largest pharma in the World) and Eisai (49th). Personally now they have been refinanced by the placing and open offer @ 15p a share I can't see any way they won't get more, and a lot more.

All IMHO.